Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Category Archives: Aditxt Inc. ADTX

Aditxt, Inc. (NASDAQ: ADTX) Bolsters Goal to Conduct First-In-Human Clinical Trial Evaluating ADI(TM) Tech with Formation of Adimune, Inc. Subsidiary; Appoints Industry Veteran as Subsidiary Chairman and CEO

Posted on January 10, 2023 by MissionIR

Aditxt (NASDAQ: ADTX), a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, on January 3, 2023 announced the formation of a U.S.-based wholly owned subsidiary, Adimune, Inc. (“Adimune(TM)”). The company also … Continue reading →

Posted in Aditxt Inc. ADTX | Leave a comment

MissionIRNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Forms Subsidiary with Focus on Immune Modulation Therapies

Posted on January 3, 2023 by MissionIR

Aditxt (NASDAQ: ADTX) is a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system. The company today announced the formation of a U.S.-based subsidiary Adimune Inc. (“Adimune(TM)”) and its plans towards submission … Continue reading →

Posted in Aditxt Inc. ADTX | Leave a comment

Aditxt Inc. (NASDAQ: ADTX) Announces Goal of First-in-Human Trials for Drug Candidate ADI(TM)-100 with a Focus on Psoriasis

Posted on December 28, 2022 by MissionIR

Aditxt (NASDAQ: ADTX), a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, is focused on mapping and reprogramming the immune system, designing technologies to provide a personalized immune profile. These technologies … Continue reading →

Posted in Aditxt Inc. ADTX | Leave a comment

MissionIRNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Featured in Equity Research Reports

Posted on November 28, 2022 by MissionIR

Aditxt (NASDAQ: ADTX), a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, was featured in recent equity research reports published by H.C. Wainwright & Co. Titled “Personalizing Precision Immunological Therapy; Initiating … Continue reading →

Posted in Aditxt Inc. ADTX | Leave a comment

MissionIRNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Announces Key Milestone in Advancing Adimune(TM) Program

Posted on October 21, 2022 by MissionIR

Aditxt (NASDAQ: ADTX) is a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system. The company today announced that its program Adimune(TM) has initiated the GMP manufacturing of drug candidate ADI(TM)-100 as … Continue reading →

Posted in Aditxt Inc. ADTX | Leave a comment

MissionIRNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Announces Publication of Innovative Mathematical Model

Posted on October 12, 2022 by MissionIR

Aditxt (NASDAQ: ADTX), a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announced publication of a mathematical model for predicting the durability and rate of decay of neutralizing antibodies to … Continue reading →

Posted in Aditxt Inc. ADTX | Leave a comment

MissionIRNewsBreaks – Aditxt Inc.’s (NASDAQ: ADTX) AditxtScore(TM) Featured in FedEx Video Presentation

Posted on October 7, 2022 by MissionIR

Aditxt (NASDAQ: ADTX), a biotech innovation company, has announced that its AditxtScore(TM) is featured by FedEx in a video presentation that showcases the various ways in which both companies are playing critical roles in a challenging environment that includes the … Continue reading →

Posted in Aditxt Inc. ADTX | Leave a comment